Neurodiagnostics Market by Product (Diagnostic & Imaging Systems (MRI, Ultrasound), Clinical Testing (PCR, NGS), Reagents & Consumables), Disease Pathology (Epilepsy, Stroke), End User, and Region - Global Forecast to 2024
“The global neurodiagnostics market is projected to grow at a CAGR of 7.3% during the forecast period.”
The global neurodiagnostics market is expected to reach USD 8.4 billion by 2024 from USD 5.9 billion in 2019, at a CAGR of 7.3%. The demand for neurodiagnostic products is expected to grow due to the increasing prevalence of neurological disorders & diseases. The neurodiagnostics market is segmented on product, condition, end-user, and region.
“The hospitals & surgical centers segment accounted for the largest share of the neurodiagnostics market by end-user in 2018.”
Based on end-user, the neurodiagnostics market is segmented into hospitals & surgical centers, diagnostic laboratories & imaging centers, neurology centers, ambulatory care centers (ACCs), and research laboratories & academic institutes. In 2018, hospitals & surgical centers accounted for the largest share of the neurodiagnostics market due to the financial capabilities of hospitals to purchase expensive equipment, such as neurodiagnostic devices.
“The neurodegenerative diseases segment accounted for the largest share of the neurodiagnostics market by condition in 2018.”
The neurodiagnostics market, by condition, is segmented into neurodegenerative diseases, epilepsy, stroke, headache disorders, sleep disorders, and other conditions. In 2019, the neurodegenerative diseases segment is expected to account for the largest share of the neurodiagnostics market due to the increasing incidence of traumatic brain injuries, dementia, Parkinson’s disease, and Huntington’s disease, and the growing number of neurological examinations for the diagnosis of these conditions.
“North America accounted for the largest share of the neurodiagnostics market in 2018.”
North America accounted for the largest share of the neurodiagnostics market in 2018, followed by Europe. This can primarily be attributed to the presence of a highly developed healthcare system, high adoption of innovative neurodiagnostic devices among medical professionals, full availability of advanced neurodiagnostic tools, and the large number of neurodiagnostic devices manufacturing companies that have an established base or are headquartered in the US.
Breakdown of supply-side primary interviews:
Research Coverage
This report studies the neurodiagnostics market based on product, condition, end-user, and region. It studies major factors (such as drivers and restraints) affecting market growth. The report also analyzes opportunities and challenges in the market for stakeholders and provides details of the competitive landscape for market leaders. It analyzes micromarkets with respect to their individual growth trends, prospects, and contributions to the total market. The report forecasts the revenue of market segments with respect to five major regions and their respective major countries.
Key Benefits of Buying the Report
This report focuses on various levels of analysis—industry trends, market shares of top players, and company profiles, which together form basic views. It also analyzes the competitive landscape; emerging segments of the neurodiagnostics market; and high-growth regions and their drivers, restraints, challenges, and opportunities. The report will help both established firms as well as new entrants/smaller firms to gauge the pulse of the market and garner greater market shares.
The global neurodiagnostics market is expected to reach USD 8.4 billion by 2024 from USD 5.9 billion in 2019, at a CAGR of 7.3%. The demand for neurodiagnostic products is expected to grow due to the increasing prevalence of neurological disorders & diseases. The neurodiagnostics market is segmented on product, condition, end-user, and region.
“The hospitals & surgical centers segment accounted for the largest share of the neurodiagnostics market by end-user in 2018.”
Based on end-user, the neurodiagnostics market is segmented into hospitals & surgical centers, diagnostic laboratories & imaging centers, neurology centers, ambulatory care centers (ACCs), and research laboratories & academic institutes. In 2018, hospitals & surgical centers accounted for the largest share of the neurodiagnostics market due to the financial capabilities of hospitals to purchase expensive equipment, such as neurodiagnostic devices.
“The neurodegenerative diseases segment accounted for the largest share of the neurodiagnostics market by condition in 2018.”
The neurodiagnostics market, by condition, is segmented into neurodegenerative diseases, epilepsy, stroke, headache disorders, sleep disorders, and other conditions. In 2019, the neurodegenerative diseases segment is expected to account for the largest share of the neurodiagnostics market due to the increasing incidence of traumatic brain injuries, dementia, Parkinson’s disease, and Huntington’s disease, and the growing number of neurological examinations for the diagnosis of these conditions.
“North America accounted for the largest share of the neurodiagnostics market in 2018.”
North America accounted for the largest share of the neurodiagnostics market in 2018, followed by Europe. This can primarily be attributed to the presence of a highly developed healthcare system, high adoption of innovative neurodiagnostic devices among medical professionals, full availability of advanced neurodiagnostic tools, and the large number of neurodiagnostic devices manufacturing companies that have an established base or are headquartered in the US.
Breakdown of supply-side primary interviews:
- By Company Type: Tier 1 (48%), Tier 2 (36%), and Tier 3 (16%)
- By Designation: C-level (10%), Director-level (14%), and Others (76%)
- By Region: North America (40%), Europe (32%), APAC (20%), and RoW (8%)
Research Coverage
This report studies the neurodiagnostics market based on product, condition, end-user, and region. It studies major factors (such as drivers and restraints) affecting market growth. The report also analyzes opportunities and challenges in the market for stakeholders and provides details of the competitive landscape for market leaders. It analyzes micromarkets with respect to their individual growth trends, prospects, and contributions to the total market. The report forecasts the revenue of market segments with respect to five major regions and their respective major countries.
Key Benefits of Buying the Report
This report focuses on various levels of analysis—industry trends, market shares of top players, and company profiles, which together form basic views. It also analyzes the competitive landscape; emerging segments of the neurodiagnostics market; and high-growth regions and their drivers, restraints, challenges, and opportunities. The report will help both established firms as well as new entrants/smaller firms to gauge the pulse of the market and garner greater market shares.
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 MARKET SCOPE
1.3.1 MARKETS COVERED
1.3.2 YEARS CONSIDERED FOR THE STUDY
1.4 CURRENCY USED FOR THE STUDY
1.5 MAJOR STAKEHOLDERS
2 RESEARCH METHODOLOGY
2.1 RESEARCH DATA
2.1.1 SECONDARY DATA
2.1.1.1 Secondary sources
2.1.2 PRIMARY DATA
2.2 MARKET ESTIMATION METHODOLOGY
2.2.1 END USER-BASED MARKET ESTIMATION
2.2.2 REVENUE MAPPING-BASED MARKET ESTIMATION
2.2.3 PRIMARY RESEARCH VALIDATION
2.3 DATA TRIANGULATION
2.4 RESEARCH ASSUMPTIONS
2.5 RESEARCH LIMITATIONS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
4.1 MARKET OVERVIEW
4.2 NEURODIAGNOSTICS MARKET, BY PRODUCT, 2019 VS. 2024
4.3 NEURODIAGNOSTICS MARKET SHARE, BY END USER AND REGION (2019)
4.4 NEURODIAGNOSTICS MARKET, BY CONDITION, 2019 VS. 2024 (USD MILLION)
4.5 NEURODIAGNOSTICS MARKET, BY COUNTRY
5 MARKET OVERVIEW
5.1 INTRODUCTION
5.2 MARKET DYNAMICS
5.2.1 DRIVERS
5.2.1.1 Increasing prevalence of neurological diseases & disorders
5.2.1.2 Technological advancements
5.2.1.3 Growing patient emphasis on effective and early disease diagnosis
5.2.1.4 Increasing number of diagnostic centers & hospitals
5.2.1.5 Advances in genomics and proteomics for the diagnosis of neurodegenerative disorders
5.2.2 RESTRAINTS
5.2.2.1 High cost of neurodiagnostic devices
5.2.2.2 Growing adoption of refurbished neurodiagnostic systems
5.2.3 OPPORTUNITIES
5.2.3.1 Increasing application of neurodiagnostic devices in clinical trials
5.2.3.2 Emerging markets
5.2.4 CHALLENGES
5.2.4.1 Dearth of skilled personnel
6 NEURODIAGNOSTICS MARKET, BY PRODUCT
6.1 INTRODUCTION
6.2 DIAGNOSTIC IMAGING SYSTEMS
6.2.1 GROWING NUMBER OF DIAGNOSTIC CENTERS TO DRIVE THE ADOPTION OF DIAGNOSTIC IMAGING SYSTEMS
6.2.1.1 MRI systems
6.2.1.2 EEG systems
6.2.1.3 CT scanners
6.2.1.4 PET scanners
6.2.1.5 EMG devices
6.2.1.6 Ultrasound imaging systems
6.2.1.7 MEG devices
6.2.1.8 Angiography systems
6.2.1.9 Other diagnostic imaging systems
6.3 CLINICAL DIAGNOSTIC INSTRUMENTS
6.3.1 INCREASING PUBLIC-PRIVATE INVESTMENTS ARE SUPPORTING
THE GROWTH OF THIS MARKET SEGMENT
6.3.1.1 PCR instruments
6.3.1.2 NGS instruments
6.3.1.3 Sanger sequencers
6.3.1.4 Other clinical diagnostic instruments
6.4 REAGENTS & CONSUMABLES
6.4.1 HIGH CONSUMPTION OF REAGENTS IN VARIOUS ROUTINE
ASSAYS & TECHNIQUES IS DRIVING THE GROWTH OF THIS SEGMENT
6.4.1.1 Media & sera
6.4.1.2 Antibodies
6.4.1.3 Buffers
6.4.1.4 Solvents
6.4.1.5 Enzymes, proteins, & peptides
6.4.1.6 Probes
6.4.1.7 Other reagents & consumables
7 NEURODIAGNOSTICS MARKET, BY CONDITION
7.1 INTRODUCTION
7.2 NEURODEGENERATIVE DISEASES
7.2.1 GROWING NUMBER OF NEUROLOGICAL EXAMINATIONS IS SUPPORTING THE GROWTH OF THIS SEGMENT
7.3 STROKE
7.3.1 GROWING AWARENESS ABOUT STROKE AND ITS TREATMENT OPTIONS TO SUPPORT MARKET GROWTH
7.4 EPILEPSY
7.4.1 FAVORABLE GOVERNMENT INITIATIVES HAVE RESULTED IN THE INCREASED ADOPTION OF NEURODIAGNOSTIC PRODUCTS
7.5 HEADACHE DISORDERS
7.5.1 INCREASING INCIDENCE OF MIGRAINES & TENSION HEADACHES TO SUPPORT MARKET GROWTH
7.6 SLEEP DISORDERS
7.6.1 INCREASING STRESS & UNHEALTHY LIFESTYLES ARE SUPPORTING THE GROWTH OF THIS MARKET SEGMENT
7.7 OTHER CONDITIONS
8 NEURODIAGNOSTICS MARKET, BY END USER
8.1 INTRODUCTION
8.2 HOSPITALS & SURGICAL CENTERS
8.2.1 HOSPITALS & SURGICAL CENTERS TO DOMINATE THE MARKET OWING TO THEIR HIGH PURCHASING POWER
8.3 DIAGNOSTIC LABORATORIES & IMAGING CENTERS
8.3.1 GROWING NUMBER OF PRIVATE IMAGING CENTERS TO SUPPORT THE GROWTH OF THIS END-USER SEGMENT
8.4 NEUROLOGY CENTERS
8.4.1 LOWER COSTS AND SHORTER WAITING PERIODS COMPARED TO HOSPITALS TO DRIVE MARKET GROWTH
8.5 AMBULATORY CARE CENTERS
8.5.1 HIGH-QUALITY AND LOWER-COST SERVICES OFFERED BY AMBULATORY CARE CENTERS TO DRIVE MARKET GROWTH
8.6 RESEARCH LABORATORIES & ACADEMIC INSTITUTES
8.6.1 BUDGETARY LIMITATIONS FACED BY SMALL RESEARCH LABORATORIES & ACADEMIC INSTITUTES WILL RESTRAIN MARKET GROWTH
9 NEURODIAGNOSTICS MARKET, BY REGION
9.1 INTRODUCTION
9.2 NORTH AMERICA
9.2.1 US
9.2.1.1 US dominates the market due to the increased adoption of high-end neurodiagnostic systems
9.2.2 CANADA
9.2.2.1 Favorable environment for R&D in the field of neurosciences is driving market growth
9.3 EUROPE
9.3.1 GERMANY
9.3.1.1 Germany commands the largest share of the neurodiagnostics market in Europe
9.3.2 UK
9.3.2.1 Market growth in the UK is mainly driven by the increasing incidence of neurodegenerative diseases
9.3.3 FRANCE
9.3.3.1 Increasing healthcare expenditure coupled with the high-end medical infrastructure will drive the demand for neurodiagnostic devices
9.3.4 ITALY
9.3.4.1 Ongoing economic crisis in the country and rising government pressure to reduce healthcare costs may restrain market growth
9.3.5 SPAIN
9.3.5.1 Increased cost burden on the state-run health insurance system will hinder market growth
9.3.6 REST OF EUROPE
9.4 ASIA PACIFIC
9.4.1 JAPAN
9.4.1.1 Favorable reimbursement and rising prevalence of neurological disorders to propel market growth in Japan
9.4.2 CHINA
9.4.2.1 Government initiatives to modernize healthcare facilities and the rising geriatric population will drive market growth
9.4.3 INDIA
9.4.3.1 Low entry barriers have made India a prominent market to invest in
9.4.4 AUSTRALIA
9.4.4.1 Technological advancements and improving healthcare infrastructure will drive the market in Australia
9.4.5 SOUTH KOREA
9.4.5.1 Rising healthcare spending and medical coverage for neurological disease treatment will propel market growth
9.4.6 REST OF ASIA PACIFIC
9.5 LATIN AMERICA
9.5.1 BRAZIL
9.5.1.1 Inadequate accessibility to healthcare has driven the government to undertake corrective measures
9.5.2 MEXICO
9.5.2.1 Mexico is a prominent medical tourism hub for US patients
9.5.3 REST OF LATIN AMERICA
9.6 MIDDLE EAST & AFRICA
9.6.1 INFRASTRUCTURAL DEVELOPMENT AND GROWING HEALTHCARE EXPENDITURE WILL CONTRIBUTE TO MARKET GROWTH IN THE MEA
10 COMPETITIVE LANDSCAPE
10.1 OVERVIEW
10.2 MARKET SHARE ANALYSIS
10.3 COMPETITIVE SCENARIO
10.3.1 KEY PRODUCT LAUNCHES
10.3.2 KEY EXPANSIONS
10.3.3 KEY ACQUISITIONS
10.3.4 KEY PARTNERSHIPS, AGREEMENTS, AND COLLABORATIONS
10.4 COMPETITIVE LEADERSHIP MAPPING
10.4.1 VISIONARY LEADERS
10.4.2 INNOVATORS
10.4.3 DYNAMIC DIFFERENTIATORS
10.4.4 EMERGING COMPANIES
11 COMPANY PROFILES
(Business Overview, Products Offered, Recent Developments, and MnM View)*
11.1 GE HEALTHCARE
11.2 PHILIPS HEALTHCARE
11.3 SIEMENS HEALTHINEERS
11.4 HITACHI, LTD.
11.5 CANON, INC.
11.6 LIFELINES NEURO COMPANY, LLC
11.7 NATUS MEDICAL INCORPORATED
11.8 F. HOFFMANN-LA ROCHE AG
11.9 FUJIFILM HOLDINGS CORPORATION
11.10 MITSAR CO., LTD.
11.11 ADVANCED BRAIN MONITORING, INC.
11.12 THERMO FISHER SCIENTIFIC, INC.
11.13 BIO-RAD LABORATORIES
11.14 QIAGEN N.V.
11.15 NIHON KOHDEN CORPORATION
11.16 OTHER COMPANIES
11.16.1 ANT NEURO
11.16.2 FONAR CORPORATION
11.16.3 FUJIREBIO (A PART OF MIRACA GROUP)
11.16.4 DRG INSTRUMENTS GMBH
11.16.5 TECAN TRADING AG
*Details on Business Overview, Products Offered, Recent Developments, and MnM View might not be captured in case of unlisted companies.
12 APPENDIX
12.1 DISCUSSION GUIDE
12.2 KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
12.3 AVAILABLE CUSTOMIZATIONS
12.4 RELATED REPORTS
12.5 AUTHOR DETAILS
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 MARKET SCOPE
1.3.1 MARKETS COVERED
1.3.2 YEARS CONSIDERED FOR THE STUDY
1.4 CURRENCY USED FOR THE STUDY
1.5 MAJOR STAKEHOLDERS
2 RESEARCH METHODOLOGY
2.1 RESEARCH DATA
2.1.1 SECONDARY DATA
2.1.1.1 Secondary sources
2.1.2 PRIMARY DATA
2.2 MARKET ESTIMATION METHODOLOGY
2.2.1 END USER-BASED MARKET ESTIMATION
2.2.2 REVENUE MAPPING-BASED MARKET ESTIMATION
2.2.3 PRIMARY RESEARCH VALIDATION
2.3 DATA TRIANGULATION
2.4 RESEARCH ASSUMPTIONS
2.5 RESEARCH LIMITATIONS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
4.1 MARKET OVERVIEW
4.2 NEURODIAGNOSTICS MARKET, BY PRODUCT, 2019 VS. 2024
4.3 NEURODIAGNOSTICS MARKET SHARE, BY END USER AND REGION (2019)
4.4 NEURODIAGNOSTICS MARKET, BY CONDITION, 2019 VS. 2024 (USD MILLION)
4.5 NEURODIAGNOSTICS MARKET, BY COUNTRY
5 MARKET OVERVIEW
5.1 INTRODUCTION
5.2 MARKET DYNAMICS
5.2.1 DRIVERS
5.2.1.1 Increasing prevalence of neurological diseases & disorders
5.2.1.2 Technological advancements
5.2.1.3 Growing patient emphasis on effective and early disease diagnosis
5.2.1.4 Increasing number of diagnostic centers & hospitals
5.2.1.5 Advances in genomics and proteomics for the diagnosis of neurodegenerative disorders
5.2.2 RESTRAINTS
5.2.2.1 High cost of neurodiagnostic devices
5.2.2.2 Growing adoption of refurbished neurodiagnostic systems
5.2.3 OPPORTUNITIES
5.2.3.1 Increasing application of neurodiagnostic devices in clinical trials
5.2.3.2 Emerging markets
5.2.4 CHALLENGES
5.2.4.1 Dearth of skilled personnel
6 NEURODIAGNOSTICS MARKET, BY PRODUCT
6.1 INTRODUCTION
6.2 DIAGNOSTIC IMAGING SYSTEMS
6.2.1 GROWING NUMBER OF DIAGNOSTIC CENTERS TO DRIVE THE ADOPTION OF DIAGNOSTIC IMAGING SYSTEMS
6.2.1.1 MRI systems
6.2.1.2 EEG systems
6.2.1.3 CT scanners
6.2.1.4 PET scanners
6.2.1.5 EMG devices
6.2.1.6 Ultrasound imaging systems
6.2.1.7 MEG devices
6.2.1.8 Angiography systems
6.2.1.9 Other diagnostic imaging systems
6.3 CLINICAL DIAGNOSTIC INSTRUMENTS
6.3.1 INCREASING PUBLIC-PRIVATE INVESTMENTS ARE SUPPORTING
THE GROWTH OF THIS MARKET SEGMENT
6.3.1.1 PCR instruments
6.3.1.2 NGS instruments
6.3.1.3 Sanger sequencers
6.3.1.4 Other clinical diagnostic instruments
6.4 REAGENTS & CONSUMABLES
6.4.1 HIGH CONSUMPTION OF REAGENTS IN VARIOUS ROUTINE
ASSAYS & TECHNIQUES IS DRIVING THE GROWTH OF THIS SEGMENT
6.4.1.1 Media & sera
6.4.1.2 Antibodies
6.4.1.3 Buffers
6.4.1.4 Solvents
6.4.1.5 Enzymes, proteins, & peptides
6.4.1.6 Probes
6.4.1.7 Other reagents & consumables
7 NEURODIAGNOSTICS MARKET, BY CONDITION
7.1 INTRODUCTION
7.2 NEURODEGENERATIVE DISEASES
7.2.1 GROWING NUMBER OF NEUROLOGICAL EXAMINATIONS IS SUPPORTING THE GROWTH OF THIS SEGMENT
7.3 STROKE
7.3.1 GROWING AWARENESS ABOUT STROKE AND ITS TREATMENT OPTIONS TO SUPPORT MARKET GROWTH
7.4 EPILEPSY
7.4.1 FAVORABLE GOVERNMENT INITIATIVES HAVE RESULTED IN THE INCREASED ADOPTION OF NEURODIAGNOSTIC PRODUCTS
7.5 HEADACHE DISORDERS
7.5.1 INCREASING INCIDENCE OF MIGRAINES & TENSION HEADACHES TO SUPPORT MARKET GROWTH
7.6 SLEEP DISORDERS
7.6.1 INCREASING STRESS & UNHEALTHY LIFESTYLES ARE SUPPORTING THE GROWTH OF THIS MARKET SEGMENT
7.7 OTHER CONDITIONS
8 NEURODIAGNOSTICS MARKET, BY END USER
8.1 INTRODUCTION
8.2 HOSPITALS & SURGICAL CENTERS
8.2.1 HOSPITALS & SURGICAL CENTERS TO DOMINATE THE MARKET OWING TO THEIR HIGH PURCHASING POWER
8.3 DIAGNOSTIC LABORATORIES & IMAGING CENTERS
8.3.1 GROWING NUMBER OF PRIVATE IMAGING CENTERS TO SUPPORT THE GROWTH OF THIS END-USER SEGMENT
8.4 NEUROLOGY CENTERS
8.4.1 LOWER COSTS AND SHORTER WAITING PERIODS COMPARED TO HOSPITALS TO DRIVE MARKET GROWTH
8.5 AMBULATORY CARE CENTERS
8.5.1 HIGH-QUALITY AND LOWER-COST SERVICES OFFERED BY AMBULATORY CARE CENTERS TO DRIVE MARKET GROWTH
8.6 RESEARCH LABORATORIES & ACADEMIC INSTITUTES
8.6.1 BUDGETARY LIMITATIONS FACED BY SMALL RESEARCH LABORATORIES & ACADEMIC INSTITUTES WILL RESTRAIN MARKET GROWTH
9 NEURODIAGNOSTICS MARKET, BY REGION
9.1 INTRODUCTION
9.2 NORTH AMERICA
9.2.1 US
9.2.1.1 US dominates the market due to the increased adoption of high-end neurodiagnostic systems
9.2.2 CANADA
9.2.2.1 Favorable environment for R&D in the field of neurosciences is driving market growth
9.3 EUROPE
9.3.1 GERMANY
9.3.1.1 Germany commands the largest share of the neurodiagnostics market in Europe
9.3.2 UK
9.3.2.1 Market growth in the UK is mainly driven by the increasing incidence of neurodegenerative diseases
9.3.3 FRANCE
9.3.3.1 Increasing healthcare expenditure coupled with the high-end medical infrastructure will drive the demand for neurodiagnostic devices
9.3.4 ITALY
9.3.4.1 Ongoing economic crisis in the country and rising government pressure to reduce healthcare costs may restrain market growth
9.3.5 SPAIN
9.3.5.1 Increased cost burden on the state-run health insurance system will hinder market growth
9.3.6 REST OF EUROPE
9.4 ASIA PACIFIC
9.4.1 JAPAN
9.4.1.1 Favorable reimbursement and rising prevalence of neurological disorders to propel market growth in Japan
9.4.2 CHINA
9.4.2.1 Government initiatives to modernize healthcare facilities and the rising geriatric population will drive market growth
9.4.3 INDIA
9.4.3.1 Low entry barriers have made India a prominent market to invest in
9.4.4 AUSTRALIA
9.4.4.1 Technological advancements and improving healthcare infrastructure will drive the market in Australia
9.4.5 SOUTH KOREA
9.4.5.1 Rising healthcare spending and medical coverage for neurological disease treatment will propel market growth
9.4.6 REST OF ASIA PACIFIC
9.5 LATIN AMERICA
9.5.1 BRAZIL
9.5.1.1 Inadequate accessibility to healthcare has driven the government to undertake corrective measures
9.5.2 MEXICO
9.5.2.1 Mexico is a prominent medical tourism hub for US patients
9.5.3 REST OF LATIN AMERICA
9.6 MIDDLE EAST & AFRICA
9.6.1 INFRASTRUCTURAL DEVELOPMENT AND GROWING HEALTHCARE EXPENDITURE WILL CONTRIBUTE TO MARKET GROWTH IN THE MEA
10 COMPETITIVE LANDSCAPE
10.1 OVERVIEW
10.2 MARKET SHARE ANALYSIS
10.3 COMPETITIVE SCENARIO
10.3.1 KEY PRODUCT LAUNCHES
10.3.2 KEY EXPANSIONS
10.3.3 KEY ACQUISITIONS
10.3.4 KEY PARTNERSHIPS, AGREEMENTS, AND COLLABORATIONS
10.4 COMPETITIVE LEADERSHIP MAPPING
10.4.1 VISIONARY LEADERS
10.4.2 INNOVATORS
10.4.3 DYNAMIC DIFFERENTIATORS
10.4.4 EMERGING COMPANIES
11 COMPANY PROFILES
(Business Overview, Products Offered, Recent Developments, and MnM View)*
11.1 GE HEALTHCARE
11.2 PHILIPS HEALTHCARE
11.3 SIEMENS HEALTHINEERS
11.4 HITACHI, LTD.
11.5 CANON, INC.
11.6 LIFELINES NEURO COMPANY, LLC
11.7 NATUS MEDICAL INCORPORATED
11.8 F. HOFFMANN-LA ROCHE AG
11.9 FUJIFILM HOLDINGS CORPORATION
11.10 MITSAR CO., LTD.
11.11 ADVANCED BRAIN MONITORING, INC.
11.12 THERMO FISHER SCIENTIFIC, INC.
11.13 BIO-RAD LABORATORIES
11.14 QIAGEN N.V.
11.15 NIHON KOHDEN CORPORATION
11.16 OTHER COMPANIES
11.16.1 ANT NEURO
11.16.2 FONAR CORPORATION
11.16.3 FUJIREBIO (A PART OF MIRACA GROUP)
11.16.4 DRG INSTRUMENTS GMBH
11.16.5 TECAN TRADING AG
*Details on Business Overview, Products Offered, Recent Developments, and MnM View might not be captured in case of unlisted companies.
12 APPENDIX
12.1 DISCUSSION GUIDE
12.2 KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
12.3 AVAILABLE CUSTOMIZATIONS
12.4 RELATED REPORTS
12.5 AUTHOR DETAILS
LIST OF TABLES
TABLE 1 NEURODIAGNOSTICS MARKET, BY PRODUCT, 2017–2024 (USD MILLION)
TABLE 2 DIAGNOSTIC IMAGING SYSTEMS MARKET, BY TYPE, 2017–2024 (USD MILLION)
TABLE 3 DIAGNOSTIC IMAGING SYSTEMS MARKET, BY REGION, 2017–2024 (USD MILLION)
TABLE 4 DIAGNOSTIC IMAGING SYSTEMS MARKET, BY CONDITION, 2017–2024 (USD MILLION)
TABLE 5 DIAGNOSTIC IMAGING SYSTEMS MARKET, BY END USER, 2017–2024 (USD MILLION)
TABLE 6 MRI SYSTEMS MARKET, BY REGION, 2017–2024 (USD MILLION)
TABLE 7 MRI SYSTEMS MARKET, BY CONDITION, 2017–2024 (USD MILLION)
TABLE 8 MRI SYSTEMS MARKET, BY END USER, 2017–2024 (USD MILLION)
TABLE 9 EEG SYSTEMS MARKET, BY REGION, 2017–2024 (USD MILLION)
TABLE 10 EEG SYSTEMS MARKET, BY CONDITION, 2017–2024 (USD MILLION)
TABLE 11 EEG SYSTEMS MARKET, BY END USER, 2017–2024 (USD MILLION)
TABLE 12 CT SCANNERS MARKET, BY REGION, 2017–2024 (USD MILLION)
TABLE 13 CT SCANNERS MARKET, BY CONDITION, 2017–2024 (USD MILLION)
TABLE 14 CT SCANNERS MARKET, BY END USER, 2017–2024 (USD MILLION)
TABLE 15 PET SCANNERS MARKET, BY REGION, 2017–2024 (USD MILLION)
TABLE 16 PET SCANNERS MARKET, BY CONDITION, 2017–2024 (USD MILLION)
TABLE 17 PET SCANNERS MARKET, BY END USER, 2017–2024 (USD MILLION)
TABLE 18 EMG DEVICES MARKET, BY REGION, 2017–2024 (USD MILLION)
TABLE 19 EMG DEVICES MARKET, BY CONDITION, 2017–2024 (USD MILLION)
TABLE 20 EMG DEVICES MARKET, BY END USER, 2017–2024 (USD MILLION)
TABLE 21 ULTRASOUND IMAGING SYSTEMS MARKET, BY REGION, 2017–2024 (USD MILLION)
TABLE 22 ULTRASOUND IMAGING SYSTEMS MARKET, BY CONDITION, 2017–2024 (USD MILLION)
TABLE 23 ULTRASOUND IMAGING SYSTEMS MARKET, BY END USER, 2017–2024 (USD MILLION)
TABLE 24 MEG DEVICES MARKET, BY REGION, 2017–2024 (USD MILLION)
TABLE 25 MEG DEVICES MARKET, BY CONDITION, 2017–2024 (USD MILLION)
TABLE 26 MEG DEVICES MARKET, BY END USER, 2017–2024 (USD MILLION)
TABLE 27 ANGIOGRAPHY SYSTEMS MARKET, BY REGION, 2017–2024 (USD MILLION)
TABLE 28 ANGIOGRAPHY SYSTEMS MARKET, BY CONDITION, 2017–2024 (USD MILLION)
TABLE 29 ANGIOGRAPHY SYSTEMS MARKET, BY END USER, 2017–2024 (USD MILLION)
TABLE 30 OTHER DIAGNOSTIC IMAGING SYSTEMS MARKET, BY REGION, 2017–2024 (USD MILLION)
TABLE 31 OTHER DIAGNOSTIC IMAGING SYSTEMS MARKET, BY CONDITION, 2017–2024 (USD MILLION)
TABLE 32 OTHER DIAGNOSTIC IMAGING SYSTEMS MARKET, BY END USER,
2017–2024 (USD MILLION)
TABLE 33 CLINICAL DIAGNOSTIC INSTRUMENTS MARKET, BY TYPE, 2017–2024 (USD MILLION)
TABLE 34 CLINICAL DIAGNOSTIC INSTRUMENTS MARKET, BY REGION, 2017–2024 (USD MILLION)
TABLE 35 CLINICAL DIAGNOSTIC INSTRUMENTS MARKET, BY CONDITION, 2017–2024 (USD MILLION)
TABLE 36 CLINICAL DIAGNOSTIC INSTRUMENTS MARKET, BY END USER, 2017–2024 (USD MILLION)
TABLE 37 PCR INSTRUMENTS MARKET, BY REGION, 2017–2024 (USD MILLION)
TABLE 38 PCR INSTRUMENTS MARKET, BY CONDITION, 2017–2024 (USD MILLION)
TABLE 39 PCR INSTRUMENTS MARKET, BY END USER, 2017–2024 (USD MILLION)
TABLE 40 NGS INSTRUMENTS MARKET, BY REGION, 2017–2024 (USD MILLION)
TABLE 41 NGS INSTRUMENTS MARKET, BY CONDITION, 2017–2024 (USD MILLION)
TABLE 42 NGS INSTRUMENTS MARKET, BY END USER, 2017–2024 (USD MILLION)
TABLE 43 SANGER SEQUENCERS MARKET, BY REGION, 2017–2024 (USD MILLION)
TABLE 44 SANGER SEQUENCERS MARKET, BY CONDITION, 2017–2024 (USD MILLION)
TABLE 45 SANGER SEQUENCERS MARKET, BY END USER, 2017–2024 (USD MILLION)
TABLE 46 OTHER CLINICAL DIAGNOSTIC INSTRUMENTS MARKET, BY REGION, 2017–2024 (USD MILLION)
TABLE 47 OTHER CLINICAL DIAGNOSTIC INSTRUMENTS MARKET, BY CONDITION, 2017–2024 (USD MILLION)
TABLE 48 OTHER CLINICAL DIAGNOSTIC INSTRUMENTS MARKET, BY END USER, 2017–2024 (USD MILLION)
TABLE 49 REAGENTS & CONSUMABLES MARKET, BY TYPE, 2017–2024 (USD MILLION)
TABLE 50 REAGENTS & CONSUMABLES MARKET, BY REGION, 2017–2024 (USD MILLION)
TABLE 51 REAGENTS & CONSUMABLES MARKET, BY CONDITION, 2017–2024 (USD MILLION)
TABLE 52 REAGENTS & CONSUMABLES MARKET, BY END USER, 2017–2024 (USD MILLION)
TABLE 53 MEDIA & SERA MARKET, BY REGION, 2017–2024 (USD MILLION)
TABLE 54 MEDIA & SERA MARKET, BY CONDITION, 2017–2024 (USD MILLION)
TABLE 55 MEDIA & SERA MARKET, BY END USER, 2017–2024 (USD MILLION)
TABLE 56 ANTIBODIES MARKET, BY REGION, 2017–2024 (USD MILLION)
TABLE 57 ANTIBODIES MARKET, BY CONDITION, 2017–2024 (USD MILLION)
TABLE 58 ANTIBODIES MARKET, BY END USER, 2017–2024 (USD MILLION)
TABLE 59 BUFFERS MARKET, BY REGION, 2017–2024 (USD MILLION)
TABLE 60 BUFFERS MARKET, BY CONDITION, 2017–2024 (USD MILLION)
TABLE 61 BUFFERS MARKET, BY END USER, 2017–2024 (USD MILLION)
TABLE 62 SOLVENTS MARKET, BY REGION, 2017–2024 (USD MILLION)
TABLE 63 SOLVENTS MARKET, BY CONDITION, 2017–2024 (USD MILLION)
TABLE 64 SOLVENTS MARKET, BY END USER, 2017–2024 (USD MILLION)
TABLE 65 ENZYMES, PROTEINS, AND PEPTIDES MARKET, BY REGION, 2017–2024 (USD MILLION)
TABLE 66 ENZYMES, PROTEINS, AND PEPTIDES MARKET, BY CONDITION, 2017–2024 (USD MILLION)
TABLE 67 ENZYMES, PROTEINS, AND PEPTIDES MARKET, BY END USER, 2017–2024 (USD MILLION)
TABLE 68 PROBES MARKET, BY REGION, 2017–2024 (USD MILLION)
TABLE 69 PROBES MARKET, BY CONDITION, 2017–2024 (USD MILLION)
TABLE 70 PROBES MARKET, BY END USER, 2017–2024 (USD MILLION)
TABLE 71 OTHER REAGENTS & CONSUMABLES MARKET, BY REGION,
2017–2024 (USD MILLION)
TABLE 72 OTHER REAGENTS & CONSUMABLES MARKET, BY CONDITION, 2017–2024 (USD MILLION)
TABLE 73 OTHER REAGENTS & CONSUMABLES MARKET, BY END USER, 2017–2024 (USD MILLION)
TABLE 74 NEURODIAGNOSTICS MARKET, BY CONDITION, 2017–2024 (USD MILLION)
TABLE 75 NEURODIAGNOSTICS MARKET FOR NEURODEGENERATIVE DISEASES, BY REGION, 2017–2024 (USD MILLION)
TABLE 76 NEURODIAGNOSTICS MARKET FOR STROKE, BY REGION, 2017–2024 (USD MILLION)
TABLE 77 NEURODIAGNOSTICS MARKET FOR EPILEPSY, BY REGION, 2017–2024 (USD MILLION)
TABLE 78 NEURODIAGNOSTICS MARKET FOR HEADACHE DISORDERS, BY REGION, 2017–2024 (USD MILLION)
TABLE 79 NEURODIAGNOSTICS MARKET FOR SLEEP DISORDERS, BY REGION, 2017–2024 (USD MILLION)
TABLE 80 NEURODIAGNOSTICS MARKET FOR OTHER CONDITIONS, BY REGION, 2017–2024 (USD MILLION)
TABLE 81 NEURODIAGNOSTICS MARKET, BY END USER, 2017–2024 (USD MILLION)
TABLE 82 NEURODIAGNOSTICS MARKET FOR HOSPITALS & SURGICAL CENTERS, BY REGION, 2017–2024 (USD MILLION)
TABLE 83 NEURODIAGNOSTICS MARKET FOR DIAGNOSTIC LABORATORIES & IMAGING CENTERS, BY REGION, 2017–2024 (USD MILLION)
TABLE 84 NEURODIAGNOSTICS MARKET FOR NEUROLOGY CENTERS, BY REGION, 2017–2024 (USD MILLION)
TABLE 85 NEURODIAGNOSTICS MARKET FOR AMBULATORY CARE CENTERS, BY REGION, 2017–2024 (USD MILLION)
TABLE 86 NEURODIAGNOSTICS MARKET FOR RESEARCH LABORATORIES & ACADEMIC INSTITUTES, BY REGION, 2017–2024 (USD MILLION)
TABLE 87 NEURODIAGNOSTICS MARKET, BY REGION, 2017–2024 (USD MILLION)
TABLE 88 NORTH AMERICA: NEURODIAGNOSTICS MARKET, BY COUNTRY, 2017–2024 (USD MILLION)
TABLE 89 NORTH AMERICA: NEURODIAGNOSTICS MARKET, BY PRODUCT,
2017–2024 (USD MILLION)
TABLE 90 NORTH AMERICA: DIAGNOSTIC IMAGING SYSTEMS MARKET, BY TYPE, 2017–2024 (USD MILLION)
TABLE 91 NORTH AMERICA: CLINICAL DIAGNOSTIC INSTRUMENTS MARKET, BY TYPE, 2017–2024 (USD MILLION)
TABLE 92 NORTH AMERICA: REAGENTS & CONSUMABLES MARKET, BY TYPE, 2017–2024 (USD MILLION)
TABLE 93 NORTH AMERICA: NEURODIAGNOSTICS MARKET, BY CONDITION, 2017–2024 (USD MILLION)
TABLE 94 NORTH AMERICA: NEURODIAGNOSTICS MARKET, BY END USER, 2017–2024 (USD MILLION)
TABLE 95 US: NEURODIAGNOSTICS MARKET, BY PRODUCT, 2017–2024 (USD MILLION)
TABLE 96 US: DIAGNOSTIC IMAGING SYSTEMS MARKET, BY TYPE, 2017–2024 (USD MILLION)
TABLE 97 US: CLINICAL DIAGNOSTIC INSTRUMENTS MARKET, BY TYPE, 2017–2024 (USD MILLION)
TABLE 98 US: REAGENTS & CONSUMABLES MARKET, BY TYPE, 2017–2024 (USD MILLION)
TABLE 99 CANADA: NEURODIAGNOSTICS MARKET, BY PRODUCT, 2017–2024 (USD MILLION)
TABLE 100 CANADA: DIAGNOSTIC IMAGING SYSTEMS MARKET, BY TYPE, 2017–2024 (USD MILLION)
TABLE 101 CANADA: CLINICAL DIAGNOSTIC INSTRUMENTS MARKET, BY TYPE, 2017–2024 (USD MILLION)
TABLE 102 CANADA: REAGENTS & CONSUMABLES MARKET, BY TYPE, 2017–2024 (USD MILLION)
TABLE 103 EUROPE: NEURODIAGNOSTICS MARKET, BY COUNTRY, 2017–2024 (USD MILLION)
TABLE 104 EUROPE: NEURODIAGNOSTICS MARKET, BY PRODUCT, 2017–2024 (USD MILLION)
TABLE 105 EUROPE: DIAGNOSTIC IMAGING SYSTEMS MARKET, BY TYPE, 2017–2024 (USD MILLION)
TABLE 106 EUROPE: CLINICAL DIAGNOSTIC INSTRUMENTS MARKET, BY TYPE, 2017–2024 (USD MILLION)
TABLE 107 EUROPE: REAGENTS & CONSUMABLES MARKET, BY TYPE, 2017–2024 (USD MILLION)
TABLE 108 EUROPE: NEURODIAGNOSTICS MARKET, BY CONDITION, 2017–2024 (USD MILLION)
TABLE 109 EUROPE: NEURODIAGNOSTICS MARKET, BY END USER, 2017–2024 (USD MILLION)
TABLE 110 GERMANY: NEURODIAGNOSTICS MARKET, BY PRODUCT, 2017–2024 (USD MILLION)
TABLE 111 GERMANY: DIAGNOSTIC IMAGING SYSTEMS MARKET, BY TYPE, 2017–2024 (USD MILLION)
TABLE 112 GERMANY: CLINICAL DIAGNOSTIC INSTRUMENTS MARKET, BY TYPE,
2017–2024 (USD MILLION)
TABLE 113 GERMANY: REAGENTS & CONSUMABLES MARKET, BY TYPE, 2017–2024 (USD MILLION)
TABLE 114 UK: NEURODIAGNOSTICS MARKET, BY PRODUCT, 2017–2024 (USD MILLION)
TABLE 115 UK: DIAGNOSTIC IMAGING SYSTEMS MARKET, BY TYPE, 2017–2024 (USD MILLION)
TABLE 116 UK: CLINICAL DIAGNOSTIC INSTRUMENTS MARKET, BY TYPE, 2017–2024 (USD MILLION)
TABLE 117 UK: REAGENTS & CONSUMABLES MARKET, BY TYPE, 2017–2024 (USD MILLION)
TABLE 118 FRANCE: NEURODIAGNOSTICS MARKET, BY PRODUCT, 2017–2024 (USD MILLION)
TABLE 119 FRANCE: DIAGNOSTIC IMAGING SYSTEMS MARKET, BY TYPE, 2017–2024 (USD MILLION)
TABLE 120 FRANCE: CLINICAL DIAGNOSTIC INSTRUMENTS MARKET, BY TYPE, 2017–2024 (USD MILLION)
TABLE 121 FRANCE: REAGENTS & CONSUMABLES MARKET, BY TYPE, 2017–2024 (USD MILLION)
TABLE 122 ITALY: NEURODIAGNOSTICS MARKET, BY PRODUCT, 2017–2024 (USD MILLION)
TABLE 123 ITALY: DIAGNOSTIC IMAGING SYSTEMS MARKET, BY TYPE, 2017–2024 (USD MILLION)
TABLE 124 ITALY: CLINICAL DIAGNOSTIC INSTRUMENTS MARKET, BY TYPE, 2017–2024 (USD MILLION)
TABLE 125 ITALY: REAGENTS & CONSUMABLES MARKET, BY TYPE, 2017–2024 (USD MILLION)
TABLE 126 SPAIN: NEURODIAGNOSTICS MARKET, BY PRODUCT, 2017–2024 (USD MILLION)
TABLE 127 SPAIN: DIAGNOSTIC IMAGING SYSTEMS MARKET, BY TYPE, 2017–2024 (USD MILLION)
TABLE 128 SPAIN: CLINICAL DIAGNOSTIC INSTRUMENTS MARKET, BY TYPE, 2017–2024 (USD MILLION)
TABLE 129 SPAIN: REAGENTS & CONSUMABLES MARKET, BY TYPE, 2017–2024 (USD MILLION)
TABLE 130 ROE: NEURODIAGNOSTICS MARKET, BY PRODUCT, 2017–2024 (USD MILLION)
TABLE 131 ROE: DIAGNOSTIC IMAGING SYSTEMS MARKET, BY TYPE,
2017–2024 (USD MILLION)
TABLE 132 ROE: CLINICAL DIAGNOSTIC INSTRUMENTS MARKET, BY TYPE, 2017–2024 (USD MILLION)
TABLE 133 ROE: REAGENTS & CONSUMABLES MARKET, BY TYPE, 2017–2024 (USD MILLION)
TABLE 134 ASIA PACIFIC: NEURODIAGNOSTICS MARKET, BY COUNTRY, 2017–2024 (USD MILLION)
TABLE 135 ASIA PACIFIC: NEURODIAGNOSTICS MARKET, BY PRODUCT, 2017–2024 (USD MILLION)
TABLE 136 ASIA PACIFIC: DIAGNOSTIC IMAGING SYSTEMS MARKET, BY TYPE, 2017–2024 (USD MILLION)
TABLE 137 ASIA PACIFIC: CLINICAL DIAGNOSTIC INSTRUMENTS MARKET, BY TYPE,
2017–2024 (USD MILLION)
TABLE 138 ASIA PACIFIC: REAGENTS & CONSUMABLES MARKET, BY TYPE, 2017–2024 (USD MILLION)
TABLE 139 ASIA PACIFIC: NEURODIAGNOSTICS MARKET, BY CONDITION,
2017–2024 (USD MILLION)
TABLE 140 ASIA PACIFIC: NEURODIAGNOSTICS MARKET, BY END USER, 2017–2024 (USD MILLION)
TABLE 141 JAPAN: NEURODIAGNOSTICS MARKET, BY PRODUCT, 2017–2024 (USD MILLION)
TABLE 142 JAPAN: DIAGNOSTIC IMAGING SYSTEMS MARKET, BY TYPE, 2017–2024 (USD MILLION)
TABLE 143 JAPAN: CLINICAL DIAGNOSTIC INSTRUMENTS MARKET, BY TYPE, 2017–2024 (USD MILLION)
TABLE 144 JAPAN: REAGENTS & CONSUMABLES MARKET, BY TYPE, 2017–2024 (USD MILLION)
TABLE 145 CHINA: NEURODIAGNOSTICS MARKET, BY PRODUCT, 2017–2024 (USD MILLION)
TABLE 146 CHINA: DIAGNOSTIC IMAGING SYSTEMS MARKET, BY TYPE, 2017–2024 (USD MILLION)
TABLE 147 CHINA: CLINICAL DIAGNOSTIC INSTRUMENTS MARKET, BY TYPE, 2017–2024 (USD MILLION)
TABLE 148 CHINA: REAGENTS & CONSUMABLES MARKET, BY TYPE, 2017–2024 (USD MILLION)
TABLE 149 INDIA: NEURODIAGNOSTICS MARKET, BY PRODUCT, 2017–2024 (USD MILLION)
TABLE 150 INDIA: DIAGNOSTIC IMAGING SYSTEMS MARKET, BY TYPE, 2017–2024 (USD MILLION)
TABLE 151 INDIA: CLINICAL DIAGNOSTIC INSTRUMENTS MARKET, BY TYPE, 2017–2024 (USD MILLION)
TABLE 152 INDIA: REAGENTS & CONSUMABLES MARKET, BY TYPE, 2017–2024 (USD MILLION)
TABLE 153 AUSTRALIA: NEURODIAGNOSTICS MARKET, BY PRODUCT,
2017–2024 (USD MILLION)
TABLE 154 AUSTRALIA: DIAGNOSTIC IMAGING SYSTEMS MARKET, BY TYPE, 2017–2024 (USD MILLION)
TABLE 155 AUSTRALIA: CLINICAL DIAGNOSTIC INSTRUMENTS MARKET, BY TYPE, 2017–2024 (USD MILLION)
TABLE 156 AUSTRALIA: REAGENTS & CONSUMABLES MARKET, BY TYPE, 2017–2024 (USD MILLION)
TABLE 157 SOUTH KOREA: NEURODIAGNOSTICS MARKET, BY PRODUCT, 2017–2024 (USD MILLION)
TABLE 158 SOUTH KOREA: DIAGNOSTIC IMAGING SYSTEMS MARKET, BY TYPE, 2017–2024 (USD MILLION)
TABLE 159 SOUTH KOREA: CLINICAL DIAGNOSTIC INSTRUMENTS MARKET, BY TYPE, 2017–2024 (USD MILLION)
TABLE 160 SOUTH KOREA: REAGENTS & CONSUMABLES MARKET, BY TYPE, 2017–2024 (USD MILLION)
TABLE 161 REST OF ASIA PACIFIC: NEURODIAGNOSTICS MARKET, BY PRODUCT, 2017–2024 (USD MILLION)
TABLE 162 REST OF ASIA PACIFIC: DIAGNOSTIC IMAGING SYSTEMS MARKET, BY TYPE, 2017–2024 (USD MILLION)
TABLE 163 REST OF ASIA PACIFIC: CLINICAL DIAGNOSTIC INSTRUMENTS MARKET, BY TYPE, 2017–2024 (USD MILLION)
TABLE 164 REST OF ASIA PACIFIC: REAGENTS & CONSUMABLES MARKET, BY TYPE, 2017–2024 (USD MILLION)
TABLE 165 LATIN AMERICA: NEURODIAGNOSTICS MARKET, BY COUNTRY, 2017–2024 (USD MILLION)
TABLE 166 LATIN AMERICA: NEURODIAGNOSTICS MARKET, BY PRODUCT, 2017–2024 (USD MILLION)
TABLE 167 LATIN AMERICA: DIAGNOSTIC IMAGING SYSTEMS MARKET, BY TYPE, 2017–2024 (USD MILLION)
TABLE 168 LATIN AMERICA: CLINICAL DIAGNOSTIC INSTRUMENTS MARKET, BY TYPE, 2017–2024 (USD MILLION)
TABLE 169 LATIN AMERICA: REAGENTS & CONSUMABLES MARKET, BY TYPE, 2017–2024 (USD MILLION)
TABLE 170 LATIN AMERICA: NEURODIAGNOSTICS MARKET, BY CONDITION, 2017–2024 (USD MILLION)
TABLE 171 LATIN AMERICA: NEURODIAGNOSTICS MARKET, BY END USER,
2017–2024 (USD MILLION)
TABLE 172 BRAZIL: NEURODIAGNOSTICS MARKET, BY PRODUCT, 2017–2024 (USD MILLION)
TABLE 173 BRAZIL: DIAGNOSTIC IMAGING SYSTEMS MARKET, BY TYPE, 2017–2024 (USD MILLION)
TABLE 174 BRAZIL: CLINICAL DIAGNOSTIC INSTRUMENTS MARKET, BY TYPE, 2017–2024 (USD MILLION)
TABLE 175 BRAZIL: REAGENTS & CONSUMABLES MARKET, BY TYPE, 2017–2024 (USD MILLION)
TABLE 176 MEXICO: NEURODIAGNOSTICS MARKET, BY PRODUCT, 2017–2024 (USD MILLION)
TABLE 177 MEXICO: DIAGNOSTIC IMAGING SYSTEMS MARKET, BY TYPE, 2017–2024 (USD MILLION)
TABLE 178 MEXICO: CLINICAL DIAGNOSTIC INSTRUMENTS MARKET, BY TYPE,
2017–2024 (USD MILLION)
TABLE 179 MEXICO: REAGENTS & CONSUMABLES MARKET, BY TYPE, 2017–2024 (USD MILLION)
TABLE 180 REST OF LATIN AMERICA: NEURODIAGNOSTICS MARKET, BY PRODUCT,
2017–2024 (USD MILLION)
TABLE 181 REST OF LATIN AMERICA: DIAGNOSTIC IMAGING SYSTEMS MARKET, BY TYPE, 2017–2024 (USD MILLION)
TABLE 182 REST OF LATIN AMERICA: CLINICAL DIAGNOSTIC INSTRUMENTS MARKET, BY TYPE, 2017–2024 (USD MILLION)
TABLE 183 REST OF LATIN AMERICA: REAGENTS & CONSUMABLES MARKET, BY TYPE, 2017–2024 (USD MILLION)
TABLE 184 MIDDLE EAST AND AFRICA: NEURODIAGNOSTICS MARKET, BY PRODUCT, 2017–2024 (USD MILLION)
TABLE 185 MIDDLE EAST AND AFRICA: DIAGNOSTIC IMAGING SYSTEMS MARKET, BY TYPE, 2017–2024 (USD MILLION)
TABLE 186 MIDDLE EAST AND AFRICA: CLINICAL DIAGNOSTIC INSTRUMENTS MARKET, BY TYPE, 2017–2024 (USD MILLION)
TABLE 187 MIDDLE EAST AND AFRICA: REAGENTS & CONSUMABLES MARKET, BY TYPE, 2017–2024 (USD MILLION)
TABLE 188 MIDDLE EAST AND AFRICA: NEURODIAGNOSTICS MARKET, BY CONDITION, 2017–2024 (USD MILLION)
TABLE 189 MIDDLE EAST AND AFRICA: NEURODIAGNOSTICS MARKET, BY END USER, 2017–2024 (USD MILLION)
TABLE 1 NEURODIAGNOSTICS MARKET, BY PRODUCT, 2017–2024 (USD MILLION)
TABLE 2 DIAGNOSTIC IMAGING SYSTEMS MARKET, BY TYPE, 2017–2024 (USD MILLION)
TABLE 3 DIAGNOSTIC IMAGING SYSTEMS MARKET, BY REGION, 2017–2024 (USD MILLION)
TABLE 4 DIAGNOSTIC IMAGING SYSTEMS MARKET, BY CONDITION, 2017–2024 (USD MILLION)
TABLE 5 DIAGNOSTIC IMAGING SYSTEMS MARKET, BY END USER, 2017–2024 (USD MILLION)
TABLE 6 MRI SYSTEMS MARKET, BY REGION, 2017–2024 (USD MILLION)
TABLE 7 MRI SYSTEMS MARKET, BY CONDITION, 2017–2024 (USD MILLION)
TABLE 8 MRI SYSTEMS MARKET, BY END USER, 2017–2024 (USD MILLION)
TABLE 9 EEG SYSTEMS MARKET, BY REGION, 2017–2024 (USD MILLION)
TABLE 10 EEG SYSTEMS MARKET, BY CONDITION, 2017–2024 (USD MILLION)
TABLE 11 EEG SYSTEMS MARKET, BY END USER, 2017–2024 (USD MILLION)
TABLE 12 CT SCANNERS MARKET, BY REGION, 2017–2024 (USD MILLION)
TABLE 13 CT SCANNERS MARKET, BY CONDITION, 2017–2024 (USD MILLION)
TABLE 14 CT SCANNERS MARKET, BY END USER, 2017–2024 (USD MILLION)
TABLE 15 PET SCANNERS MARKET, BY REGION, 2017–2024 (USD MILLION)
TABLE 16 PET SCANNERS MARKET, BY CONDITION, 2017–2024 (USD MILLION)
TABLE 17 PET SCANNERS MARKET, BY END USER, 2017–2024 (USD MILLION)
TABLE 18 EMG DEVICES MARKET, BY REGION, 2017–2024 (USD MILLION)
TABLE 19 EMG DEVICES MARKET, BY CONDITION, 2017–2024 (USD MILLION)
TABLE 20 EMG DEVICES MARKET, BY END USER, 2017–2024 (USD MILLION)
TABLE 21 ULTRASOUND IMAGING SYSTEMS MARKET, BY REGION, 2017–2024 (USD MILLION)
TABLE 22 ULTRASOUND IMAGING SYSTEMS MARKET, BY CONDITION, 2017–2024 (USD MILLION)
TABLE 23 ULTRASOUND IMAGING SYSTEMS MARKET, BY END USER, 2017–2024 (USD MILLION)
TABLE 24 MEG DEVICES MARKET, BY REGION, 2017–2024 (USD MILLION)
TABLE 25 MEG DEVICES MARKET, BY CONDITION, 2017–2024 (USD MILLION)
TABLE 26 MEG DEVICES MARKET, BY END USER, 2017–2024 (USD MILLION)
TABLE 27 ANGIOGRAPHY SYSTEMS MARKET, BY REGION, 2017–2024 (USD MILLION)
TABLE 28 ANGIOGRAPHY SYSTEMS MARKET, BY CONDITION, 2017–2024 (USD MILLION)
TABLE 29 ANGIOGRAPHY SYSTEMS MARKET, BY END USER, 2017–2024 (USD MILLION)
TABLE 30 OTHER DIAGNOSTIC IMAGING SYSTEMS MARKET, BY REGION, 2017–2024 (USD MILLION)
TABLE 31 OTHER DIAGNOSTIC IMAGING SYSTEMS MARKET, BY CONDITION, 2017–2024 (USD MILLION)
TABLE 32 OTHER DIAGNOSTIC IMAGING SYSTEMS MARKET, BY END USER,
2017–2024 (USD MILLION)
TABLE 33 CLINICAL DIAGNOSTIC INSTRUMENTS MARKET, BY TYPE, 2017–2024 (USD MILLION)
TABLE 34 CLINICAL DIAGNOSTIC INSTRUMENTS MARKET, BY REGION, 2017–2024 (USD MILLION)
TABLE 35 CLINICAL DIAGNOSTIC INSTRUMENTS MARKET, BY CONDITION, 2017–2024 (USD MILLION)
TABLE 36 CLINICAL DIAGNOSTIC INSTRUMENTS MARKET, BY END USER, 2017–2024 (USD MILLION)
TABLE 37 PCR INSTRUMENTS MARKET, BY REGION, 2017–2024 (USD MILLION)
TABLE 38 PCR INSTRUMENTS MARKET, BY CONDITION, 2017–2024 (USD MILLION)
TABLE 39 PCR INSTRUMENTS MARKET, BY END USER, 2017–2024 (USD MILLION)
TABLE 40 NGS INSTRUMENTS MARKET, BY REGION, 2017–2024 (USD MILLION)
TABLE 41 NGS INSTRUMENTS MARKET, BY CONDITION, 2017–2024 (USD MILLION)
TABLE 42 NGS INSTRUMENTS MARKET, BY END USER, 2017–2024 (USD MILLION)
TABLE 43 SANGER SEQUENCERS MARKET, BY REGION, 2017–2024 (USD MILLION)
TABLE 44 SANGER SEQUENCERS MARKET, BY CONDITION, 2017–2024 (USD MILLION)
TABLE 45 SANGER SEQUENCERS MARKET, BY END USER, 2017–2024 (USD MILLION)
TABLE 46 OTHER CLINICAL DIAGNOSTIC INSTRUMENTS MARKET, BY REGION, 2017–2024 (USD MILLION)
TABLE 47 OTHER CLINICAL DIAGNOSTIC INSTRUMENTS MARKET, BY CONDITION, 2017–2024 (USD MILLION)
TABLE 48 OTHER CLINICAL DIAGNOSTIC INSTRUMENTS MARKET, BY END USER, 2017–2024 (USD MILLION)
TABLE 49 REAGENTS & CONSUMABLES MARKET, BY TYPE, 2017–2024 (USD MILLION)
TABLE 50 REAGENTS & CONSUMABLES MARKET, BY REGION, 2017–2024 (USD MILLION)
TABLE 51 REAGENTS & CONSUMABLES MARKET, BY CONDITION, 2017–2024 (USD MILLION)
TABLE 52 REAGENTS & CONSUMABLES MARKET, BY END USER, 2017–2024 (USD MILLION)
TABLE 53 MEDIA & SERA MARKET, BY REGION, 2017–2024 (USD MILLION)
TABLE 54 MEDIA & SERA MARKET, BY CONDITION, 2017–2024 (USD MILLION)
TABLE 55 MEDIA & SERA MARKET, BY END USER, 2017–2024 (USD MILLION)
TABLE 56 ANTIBODIES MARKET, BY REGION, 2017–2024 (USD MILLION)
TABLE 57 ANTIBODIES MARKET, BY CONDITION, 2017–2024 (USD MILLION)
TABLE 58 ANTIBODIES MARKET, BY END USER, 2017–2024 (USD MILLION)
TABLE 59 BUFFERS MARKET, BY REGION, 2017–2024 (USD MILLION)
TABLE 60 BUFFERS MARKET, BY CONDITION, 2017–2024 (USD MILLION)
TABLE 61 BUFFERS MARKET, BY END USER, 2017–2024 (USD MILLION)
TABLE 62 SOLVENTS MARKET, BY REGION, 2017–2024 (USD MILLION)
TABLE 63 SOLVENTS MARKET, BY CONDITION, 2017–2024 (USD MILLION)
TABLE 64 SOLVENTS MARKET, BY END USER, 2017–2024 (USD MILLION)
TABLE 65 ENZYMES, PROTEINS, AND PEPTIDES MARKET, BY REGION, 2017–2024 (USD MILLION)
TABLE 66 ENZYMES, PROTEINS, AND PEPTIDES MARKET, BY CONDITION, 2017–2024 (USD MILLION)
TABLE 67 ENZYMES, PROTEINS, AND PEPTIDES MARKET, BY END USER, 2017–2024 (USD MILLION)
TABLE 68 PROBES MARKET, BY REGION, 2017–2024 (USD MILLION)
TABLE 69 PROBES MARKET, BY CONDITION, 2017–2024 (USD MILLION)
TABLE 70 PROBES MARKET, BY END USER, 2017–2024 (USD MILLION)
TABLE 71 OTHER REAGENTS & CONSUMABLES MARKET, BY REGION,
2017–2024 (USD MILLION)
TABLE 72 OTHER REAGENTS & CONSUMABLES MARKET, BY CONDITION, 2017–2024 (USD MILLION)
TABLE 73 OTHER REAGENTS & CONSUMABLES MARKET, BY END USER, 2017–2024 (USD MILLION)
TABLE 74 NEURODIAGNOSTICS MARKET, BY CONDITION, 2017–2024 (USD MILLION)
TABLE 75 NEURODIAGNOSTICS MARKET FOR NEURODEGENERATIVE DISEASES, BY REGION, 2017–2024 (USD MILLION)
TABLE 76 NEURODIAGNOSTICS MARKET FOR STROKE, BY REGION, 2017–2024 (USD MILLION)
TABLE 77 NEURODIAGNOSTICS MARKET FOR EPILEPSY, BY REGION, 2017–2024 (USD MILLION)
TABLE 78 NEURODIAGNOSTICS MARKET FOR HEADACHE DISORDERS, BY REGION, 2017–2024 (USD MILLION)
TABLE 79 NEURODIAGNOSTICS MARKET FOR SLEEP DISORDERS, BY REGION, 2017–2024 (USD MILLION)
TABLE 80 NEURODIAGNOSTICS MARKET FOR OTHER CONDITIONS, BY REGION, 2017–2024 (USD MILLION)
TABLE 81 NEURODIAGNOSTICS MARKET, BY END USER, 2017–2024 (USD MILLION)
TABLE 82 NEURODIAGNOSTICS MARKET FOR HOSPITALS & SURGICAL CENTERS, BY REGION, 2017–2024 (USD MILLION)
TABLE 83 NEURODIAGNOSTICS MARKET FOR DIAGNOSTIC LABORATORIES & IMAGING CENTERS, BY REGION, 2017–2024 (USD MILLION)
TABLE 84 NEURODIAGNOSTICS MARKET FOR NEUROLOGY CENTERS, BY REGION, 2017–2024 (USD MILLION)
TABLE 85 NEURODIAGNOSTICS MARKET FOR AMBULATORY CARE CENTERS, BY REGION, 2017–2024 (USD MILLION)
TABLE 86 NEURODIAGNOSTICS MARKET FOR RESEARCH LABORATORIES & ACADEMIC INSTITUTES, BY REGION, 2017–2024 (USD MILLION)
TABLE 87 NEURODIAGNOSTICS MARKET, BY REGION, 2017–2024 (USD MILLION)
TABLE 88 NORTH AMERICA: NEURODIAGNOSTICS MARKET, BY COUNTRY, 2017–2024 (USD MILLION)
TABLE 89 NORTH AMERICA: NEURODIAGNOSTICS MARKET, BY PRODUCT,
2017–2024 (USD MILLION)
TABLE 90 NORTH AMERICA: DIAGNOSTIC IMAGING SYSTEMS MARKET, BY TYPE, 2017–2024 (USD MILLION)
TABLE 91 NORTH AMERICA: CLINICAL DIAGNOSTIC INSTRUMENTS MARKET, BY TYPE, 2017–2024 (USD MILLION)
TABLE 92 NORTH AMERICA: REAGENTS & CONSUMABLES MARKET, BY TYPE, 2017–2024 (USD MILLION)
TABLE 93 NORTH AMERICA: NEURODIAGNOSTICS MARKET, BY CONDITION, 2017–2024 (USD MILLION)
TABLE 94 NORTH AMERICA: NEURODIAGNOSTICS MARKET, BY END USER, 2017–2024 (USD MILLION)
TABLE 95 US: NEURODIAGNOSTICS MARKET, BY PRODUCT, 2017–2024 (USD MILLION)
TABLE 96 US: DIAGNOSTIC IMAGING SYSTEMS MARKET, BY TYPE, 2017–2024 (USD MILLION)
TABLE 97 US: CLINICAL DIAGNOSTIC INSTRUMENTS MARKET, BY TYPE, 2017–2024 (USD MILLION)
TABLE 98 US: REAGENTS & CONSUMABLES MARKET, BY TYPE, 2017–2024 (USD MILLION)
TABLE 99 CANADA: NEURODIAGNOSTICS MARKET, BY PRODUCT, 2017–2024 (USD MILLION)
TABLE 100 CANADA: DIAGNOSTIC IMAGING SYSTEMS MARKET, BY TYPE, 2017–2024 (USD MILLION)
TABLE 101 CANADA: CLINICAL DIAGNOSTIC INSTRUMENTS MARKET, BY TYPE, 2017–2024 (USD MILLION)
TABLE 102 CANADA: REAGENTS & CONSUMABLES MARKET, BY TYPE, 2017–2024 (USD MILLION)
TABLE 103 EUROPE: NEURODIAGNOSTICS MARKET, BY COUNTRY, 2017–2024 (USD MILLION)
TABLE 104 EUROPE: NEURODIAGNOSTICS MARKET, BY PRODUCT, 2017–2024 (USD MILLION)
TABLE 105 EUROPE: DIAGNOSTIC IMAGING SYSTEMS MARKET, BY TYPE, 2017–2024 (USD MILLION)
TABLE 106 EUROPE: CLINICAL DIAGNOSTIC INSTRUMENTS MARKET, BY TYPE, 2017–2024 (USD MILLION)
TABLE 107 EUROPE: REAGENTS & CONSUMABLES MARKET, BY TYPE, 2017–2024 (USD MILLION)
TABLE 108 EUROPE: NEURODIAGNOSTICS MARKET, BY CONDITION, 2017–2024 (USD MILLION)
TABLE 109 EUROPE: NEURODIAGNOSTICS MARKET, BY END USER, 2017–2024 (USD MILLION)
TABLE 110 GERMANY: NEURODIAGNOSTICS MARKET, BY PRODUCT, 2017–2024 (USD MILLION)
TABLE 111 GERMANY: DIAGNOSTIC IMAGING SYSTEMS MARKET, BY TYPE, 2017–2024 (USD MILLION)
TABLE 112 GERMANY: CLINICAL DIAGNOSTIC INSTRUMENTS MARKET, BY TYPE,
2017–2024 (USD MILLION)
TABLE 113 GERMANY: REAGENTS & CONSUMABLES MARKET, BY TYPE, 2017–2024 (USD MILLION)
TABLE 114 UK: NEURODIAGNOSTICS MARKET, BY PRODUCT, 2017–2024 (USD MILLION)
TABLE 115 UK: DIAGNOSTIC IMAGING SYSTEMS MARKET, BY TYPE, 2017–2024 (USD MILLION)
TABLE 116 UK: CLINICAL DIAGNOSTIC INSTRUMENTS MARKET, BY TYPE, 2017–2024 (USD MILLION)
TABLE 117 UK: REAGENTS & CONSUMABLES MARKET, BY TYPE, 2017–2024 (USD MILLION)
TABLE 118 FRANCE: NEURODIAGNOSTICS MARKET, BY PRODUCT, 2017–2024 (USD MILLION)
TABLE 119 FRANCE: DIAGNOSTIC IMAGING SYSTEMS MARKET, BY TYPE, 2017–2024 (USD MILLION)
TABLE 120 FRANCE: CLINICAL DIAGNOSTIC INSTRUMENTS MARKET, BY TYPE, 2017–2024 (USD MILLION)
TABLE 121 FRANCE: REAGENTS & CONSUMABLES MARKET, BY TYPE, 2017–2024 (USD MILLION)
TABLE 122 ITALY: NEURODIAGNOSTICS MARKET, BY PRODUCT, 2017–2024 (USD MILLION)
TABLE 123 ITALY: DIAGNOSTIC IMAGING SYSTEMS MARKET, BY TYPE, 2017–2024 (USD MILLION)
TABLE 124 ITALY: CLINICAL DIAGNOSTIC INSTRUMENTS MARKET, BY TYPE, 2017–2024 (USD MILLION)
TABLE 125 ITALY: REAGENTS & CONSUMABLES MARKET, BY TYPE, 2017–2024 (USD MILLION)
TABLE 126 SPAIN: NEURODIAGNOSTICS MARKET, BY PRODUCT, 2017–2024 (USD MILLION)
TABLE 127 SPAIN: DIAGNOSTIC IMAGING SYSTEMS MARKET, BY TYPE, 2017–2024 (USD MILLION)
TABLE 128 SPAIN: CLINICAL DIAGNOSTIC INSTRUMENTS MARKET, BY TYPE, 2017–2024 (USD MILLION)
TABLE 129 SPAIN: REAGENTS & CONSUMABLES MARKET, BY TYPE, 2017–2024 (USD MILLION)
TABLE 130 ROE: NEURODIAGNOSTICS MARKET, BY PRODUCT, 2017–2024 (USD MILLION)
TABLE 131 ROE: DIAGNOSTIC IMAGING SYSTEMS MARKET, BY TYPE,
2017–2024 (USD MILLION)
TABLE 132 ROE: CLINICAL DIAGNOSTIC INSTRUMENTS MARKET, BY TYPE, 2017–2024 (USD MILLION)
TABLE 133 ROE: REAGENTS & CONSUMABLES MARKET, BY TYPE, 2017–2024 (USD MILLION)
TABLE 134 ASIA PACIFIC: NEURODIAGNOSTICS MARKET, BY COUNTRY, 2017–2024 (USD MILLION)
TABLE 135 ASIA PACIFIC: NEURODIAGNOSTICS MARKET, BY PRODUCT, 2017–2024 (USD MILLION)
TABLE 136 ASIA PACIFIC: DIAGNOSTIC IMAGING SYSTEMS MARKET, BY TYPE, 2017–2024 (USD MILLION)
TABLE 137 ASIA PACIFIC: CLINICAL DIAGNOSTIC INSTRUMENTS MARKET, BY TYPE,
2017–2024 (USD MILLION)
TABLE 138 ASIA PACIFIC: REAGENTS & CONSUMABLES MARKET, BY TYPE, 2017–2024 (USD MILLION)
TABLE 139 ASIA PACIFIC: NEURODIAGNOSTICS MARKET, BY CONDITION,
2017–2024 (USD MILLION)
TABLE 140 ASIA PACIFIC: NEURODIAGNOSTICS MARKET, BY END USER, 2017–2024 (USD MILLION)
TABLE 141 JAPAN: NEURODIAGNOSTICS MARKET, BY PRODUCT, 2017–2024 (USD MILLION)
TABLE 142 JAPAN: DIAGNOSTIC IMAGING SYSTEMS MARKET, BY TYPE, 2017–2024 (USD MILLION)
TABLE 143 JAPAN: CLINICAL DIAGNOSTIC INSTRUMENTS MARKET, BY TYPE, 2017–2024 (USD MILLION)
TABLE 144 JAPAN: REAGENTS & CONSUMABLES MARKET, BY TYPE, 2017–2024 (USD MILLION)
TABLE 145 CHINA: NEURODIAGNOSTICS MARKET, BY PRODUCT, 2017–2024 (USD MILLION)
TABLE 146 CHINA: DIAGNOSTIC IMAGING SYSTEMS MARKET, BY TYPE, 2017–2024 (USD MILLION)
TABLE 147 CHINA: CLINICAL DIAGNOSTIC INSTRUMENTS MARKET, BY TYPE, 2017–2024 (USD MILLION)
TABLE 148 CHINA: REAGENTS & CONSUMABLES MARKET, BY TYPE, 2017–2024 (USD MILLION)
TABLE 149 INDIA: NEURODIAGNOSTICS MARKET, BY PRODUCT, 2017–2024 (USD MILLION)
TABLE 150 INDIA: DIAGNOSTIC IMAGING SYSTEMS MARKET, BY TYPE, 2017–2024 (USD MILLION)
TABLE 151 INDIA: CLINICAL DIAGNOSTIC INSTRUMENTS MARKET, BY TYPE, 2017–2024 (USD MILLION)
TABLE 152 INDIA: REAGENTS & CONSUMABLES MARKET, BY TYPE, 2017–2024 (USD MILLION)
TABLE 153 AUSTRALIA: NEURODIAGNOSTICS MARKET, BY PRODUCT,
2017–2024 (USD MILLION)
TABLE 154 AUSTRALIA: DIAGNOSTIC IMAGING SYSTEMS MARKET, BY TYPE, 2017–2024 (USD MILLION)
TABLE 155 AUSTRALIA: CLINICAL DIAGNOSTIC INSTRUMENTS MARKET, BY TYPE, 2017–2024 (USD MILLION)
TABLE 156 AUSTRALIA: REAGENTS & CONSUMABLES MARKET, BY TYPE, 2017–2024 (USD MILLION)
TABLE 157 SOUTH KOREA: NEURODIAGNOSTICS MARKET, BY PRODUCT, 2017–2024 (USD MILLION)
TABLE 158 SOUTH KOREA: DIAGNOSTIC IMAGING SYSTEMS MARKET, BY TYPE, 2017–2024 (USD MILLION)
TABLE 159 SOUTH KOREA: CLINICAL DIAGNOSTIC INSTRUMENTS MARKET, BY TYPE, 2017–2024 (USD MILLION)
TABLE 160 SOUTH KOREA: REAGENTS & CONSUMABLES MARKET, BY TYPE, 2017–2024 (USD MILLION)
TABLE 161 REST OF ASIA PACIFIC: NEURODIAGNOSTICS MARKET, BY PRODUCT, 2017–2024 (USD MILLION)
TABLE 162 REST OF ASIA PACIFIC: DIAGNOSTIC IMAGING SYSTEMS MARKET, BY TYPE, 2017–2024 (USD MILLION)
TABLE 163 REST OF ASIA PACIFIC: CLINICAL DIAGNOSTIC INSTRUMENTS MARKET, BY TYPE, 2017–2024 (USD MILLION)
TABLE 164 REST OF ASIA PACIFIC: REAGENTS & CONSUMABLES MARKET, BY TYPE, 2017–2024 (USD MILLION)
TABLE 165 LATIN AMERICA: NEURODIAGNOSTICS MARKET, BY COUNTRY, 2017–2024 (USD MILLION)
TABLE 166 LATIN AMERICA: NEURODIAGNOSTICS MARKET, BY PRODUCT, 2017–2024 (USD MILLION)
TABLE 167 LATIN AMERICA: DIAGNOSTIC IMAGING SYSTEMS MARKET, BY TYPE, 2017–2024 (USD MILLION)
TABLE 168 LATIN AMERICA: CLINICAL DIAGNOSTIC INSTRUMENTS MARKET, BY TYPE, 2017–2024 (USD MILLION)
TABLE 169 LATIN AMERICA: REAGENTS & CONSUMABLES MARKET, BY TYPE, 2017–2024 (USD MILLION)
TABLE 170 LATIN AMERICA: NEURODIAGNOSTICS MARKET, BY CONDITION, 2017–2024 (USD MILLION)
TABLE 171 LATIN AMERICA: NEURODIAGNOSTICS MARKET, BY END USER,
2017–2024 (USD MILLION)
TABLE 172 BRAZIL: NEURODIAGNOSTICS MARKET, BY PRODUCT, 2017–2024 (USD MILLION)
TABLE 173 BRAZIL: DIAGNOSTIC IMAGING SYSTEMS MARKET, BY TYPE, 2017–2024 (USD MILLION)
TABLE 174 BRAZIL: CLINICAL DIAGNOSTIC INSTRUMENTS MARKET, BY TYPE, 2017–2024 (USD MILLION)
TABLE 175 BRAZIL: REAGENTS & CONSUMABLES MARKET, BY TYPE, 2017–2024 (USD MILLION)
TABLE 176 MEXICO: NEURODIAGNOSTICS MARKET, BY PRODUCT, 2017–2024 (USD MILLION)
TABLE 177 MEXICO: DIAGNOSTIC IMAGING SYSTEMS MARKET, BY TYPE, 2017–2024 (USD MILLION)
TABLE 178 MEXICO: CLINICAL DIAGNOSTIC INSTRUMENTS MARKET, BY TYPE,
2017–2024 (USD MILLION)
TABLE 179 MEXICO: REAGENTS & CONSUMABLES MARKET, BY TYPE, 2017–2024 (USD MILLION)
TABLE 180 REST OF LATIN AMERICA: NEURODIAGNOSTICS MARKET, BY PRODUCT,
2017–2024 (USD MILLION)
TABLE 181 REST OF LATIN AMERICA: DIAGNOSTIC IMAGING SYSTEMS MARKET, BY TYPE, 2017–2024 (USD MILLION)
TABLE 182 REST OF LATIN AMERICA: CLINICAL DIAGNOSTIC INSTRUMENTS MARKET, BY TYPE, 2017–2024 (USD MILLION)
TABLE 183 REST OF LATIN AMERICA: REAGENTS & CONSUMABLES MARKET, BY TYPE, 2017–2024 (USD MILLION)
TABLE 184 MIDDLE EAST AND AFRICA: NEURODIAGNOSTICS MARKET, BY PRODUCT, 2017–2024 (USD MILLION)
TABLE 185 MIDDLE EAST AND AFRICA: DIAGNOSTIC IMAGING SYSTEMS MARKET, BY TYPE, 2017–2024 (USD MILLION)
TABLE 186 MIDDLE EAST AND AFRICA: CLINICAL DIAGNOSTIC INSTRUMENTS MARKET, BY TYPE, 2017–2024 (USD MILLION)
TABLE 187 MIDDLE EAST AND AFRICA: REAGENTS & CONSUMABLES MARKET, BY TYPE, 2017–2024 (USD MILLION)
TABLE 188 MIDDLE EAST AND AFRICA: NEURODIAGNOSTICS MARKET, BY CONDITION, 2017–2024 (USD MILLION)
TABLE 189 MIDDLE EAST AND AFRICA: NEURODIAGNOSTICS MARKET, BY END USER, 2017–2024 (USD MILLION)
LIST OF FIGURES
FIGURE 1 RESEARCH DESIGN
FIGURE 2 BREAKDOWN OF PRIMARIES: NEURODIAGNOSTICS MARKET
FIGURE 3 RESEARCH METHODOLOGY: HYPOTHESIS BUILDING
FIGURE 4 MARKET SIZE ESTIMATION: NEURODIAGNOSTICS MARKET
FIGURE 5 DATA TRIANGULATION METHODOLOGY
FIGURE 6 NEURODIAGNOSTICS MARKET, BY PRODUCT, 2019 VS. 2024 (USD MILLION)
FIGURE 7 NEURODIAGNOSTICS MARKET SHARE, BY CONDITION, 2019 VS. 2024
FIGURE 8 NEURODIAGNOSTICS MARKET SHARE, BY END USER, 2019 VS. 2024
FIGURE 9 GEOGRAPHIC SNAPSHOT: NEURODIAGNOSTICS MARKET
FIGURE 10 INCREASING PREVALENCE OF NEUROLOGICAL DISORDERS TO DRIVE THE
DEMAND FOR NEURODIAGNOSTIC DEVICES
FIGURE 11 DIAGNOSTIC IMAGING SYSTEMS TO REGISTER THE HIGHEST CAGR DURING THE FORECAST PERIOD
FIGURE 12 NORTH AMERICA TO DOMINATE THE NEURODIAGNOSTICS MARKET
FIGURE 13 NEURODEGENERATIVE DISEASES SEGMENT TO DOMINATE THE MARKET DURING THE FORECAST PERIOD
FIGURE 14 CHINA IS ESTIMATED TO BE THE FASTEST-GROWING MARKET FOR NEURODIAGNOSTICS
FIGURE 15 NEURODIAGNOSTICS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
FIGURE 16 NORTH AMERICA: NEURODIAGNOSTICS MARKET SNAPSHOT
FIGURE 17 ASIA PACIFIC: NEURODIAGNOSTICS MARKET SNAPSHOT
FIGURE 18 KEY DEVELOPMENTS IN THE NEURODIAGNOSTICS MARKET, 2016–2019
FIGURE 19 GE HEALTHCARE HELD THE LEADING POSITION IN THE NEURODIAGNOSTICS MARKET IN 2018
FIGURE 20 NEURODIAGNOSTICS MARKET (GLOBAL) COMPETITIVE LEADERSHIP
MAPPING, 2018
FIGURE 21 GE HEALTHCARE: COMPANY SNAPSHOT
FIGURE 22 PHILIPS HEALTHCARE: COMPANY SNAPSHOT
FIGURE 23 SIEMENS HEALTHINEERS: COMPANY SNAPSHOT
FIGURE 24 HITACHI, LTD.: COMPANY SNAPSHOT
FIGURE 25 CANON, INC.: COMPANY SNAPSHOT
FIGURE 26 NATUS MEDICAL INCORPORATED: COMPANY SNAPSHOT
FIGURE 27 F. HOFFMANN-LA ROCHE AG: COMPANY SNAPSHOT
FIGURE 28 FUJIFILM HOLDINGS CORPORATION: COMPANY SNAPSHOT
FIGURE 29 THERMO FISHER SCIENTIFIC, INC.: COMPANY SNAPSHOT
FIGURE 30 BIO-RAD LABORATORIES: COMPANY SNAPSHOT
FIGURE 31 QIAGEN N.V.: COMPANY SNAPSHOT
FIGURE 32 NIHON KOHDEN: COMPANY SNAPSHOT
FIGURE 1 RESEARCH DESIGN
FIGURE 2 BREAKDOWN OF PRIMARIES: NEURODIAGNOSTICS MARKET
FIGURE 3 RESEARCH METHODOLOGY: HYPOTHESIS BUILDING
FIGURE 4 MARKET SIZE ESTIMATION: NEURODIAGNOSTICS MARKET
FIGURE 5 DATA TRIANGULATION METHODOLOGY
FIGURE 6 NEURODIAGNOSTICS MARKET, BY PRODUCT, 2019 VS. 2024 (USD MILLION)
FIGURE 7 NEURODIAGNOSTICS MARKET SHARE, BY CONDITION, 2019 VS. 2024
FIGURE 8 NEURODIAGNOSTICS MARKET SHARE, BY END USER, 2019 VS. 2024
FIGURE 9 GEOGRAPHIC SNAPSHOT: NEURODIAGNOSTICS MARKET
FIGURE 10 INCREASING PREVALENCE OF NEUROLOGICAL DISORDERS TO DRIVE THE
DEMAND FOR NEURODIAGNOSTIC DEVICES
FIGURE 11 DIAGNOSTIC IMAGING SYSTEMS TO REGISTER THE HIGHEST CAGR DURING THE FORECAST PERIOD
FIGURE 12 NORTH AMERICA TO DOMINATE THE NEURODIAGNOSTICS MARKET
FIGURE 13 NEURODEGENERATIVE DISEASES SEGMENT TO DOMINATE THE MARKET DURING THE FORECAST PERIOD
FIGURE 14 CHINA IS ESTIMATED TO BE THE FASTEST-GROWING MARKET FOR NEURODIAGNOSTICS
FIGURE 15 NEURODIAGNOSTICS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
FIGURE 16 NORTH AMERICA: NEURODIAGNOSTICS MARKET SNAPSHOT
FIGURE 17 ASIA PACIFIC: NEURODIAGNOSTICS MARKET SNAPSHOT
FIGURE 18 KEY DEVELOPMENTS IN THE NEURODIAGNOSTICS MARKET, 2016–2019
FIGURE 19 GE HEALTHCARE HELD THE LEADING POSITION IN THE NEURODIAGNOSTICS MARKET IN 2018
FIGURE 20 NEURODIAGNOSTICS MARKET (GLOBAL) COMPETITIVE LEADERSHIP
MAPPING, 2018
FIGURE 21 GE HEALTHCARE: COMPANY SNAPSHOT
FIGURE 22 PHILIPS HEALTHCARE: COMPANY SNAPSHOT
FIGURE 23 SIEMENS HEALTHINEERS: COMPANY SNAPSHOT
FIGURE 24 HITACHI, LTD.: COMPANY SNAPSHOT
FIGURE 25 CANON, INC.: COMPANY SNAPSHOT
FIGURE 26 NATUS MEDICAL INCORPORATED: COMPANY SNAPSHOT
FIGURE 27 F. HOFFMANN-LA ROCHE AG: COMPANY SNAPSHOT
FIGURE 28 FUJIFILM HOLDINGS CORPORATION: COMPANY SNAPSHOT
FIGURE 29 THERMO FISHER SCIENTIFIC, INC.: COMPANY SNAPSHOT
FIGURE 30 BIO-RAD LABORATORIES: COMPANY SNAPSHOT
FIGURE 31 QIAGEN N.V.: COMPANY SNAPSHOT
FIGURE 32 NIHON KOHDEN: COMPANY SNAPSHOT
